Two Important Updates on Iovance Biotherapeutics

Dear Biotech Frontiers Subscribers: We have two timely pieces of news to digest. 1. This past Friday, February 16, the Food and Drug Administration (“FDA”) granted Iovance Biotherapeutics’ (Nasdaq: IOVA) lifileucel therapy accelerated approval for advanced melanoma, making it the first and only tumor-infiltrating lymphocyte (“TIL”) treatment available for cancer. Lifileucel’s approval is an important
Read More …

Buy Alert: IOVA for Biotech Frontiers Portfolio

Dear Porter & Co. Biotech Frontiers Subscribers: One of the defining aspects of biotech is that it’s a catalyst-driven investment domain. This means that the fate of biotech investments often depends on specific, concrete events – such as clinical-trial-data releases or regulatory decisions. These decisions can drive biotech stocks much higher… or much lower.   This
Read More …

Action to Take: Sell Half of Sagimet Biosciences

Dear Porter & Co. Biotech Frontiers Subscribers: On January 22, Sagimet Biosciences (Nasdaq: SGMT) – a member of our inaugural 10-stock basket kicking off our portfolio – announced top-line results from the Phase 2b clinical trial of its lead drug candidate, Denifanstat. Denifanstat is a promising treatment for liver fibrosis and NASH, serious metabolic illnesses that afflict
Read More …

The Big Biotech Rebound

We’re in the midst of the longest and most punishing bear market in the history of biotech. Investors are so repelled by the sector that they’re ascribing negative value to many of its companies, creating the perfect opportunity for biotech investors. That’s why in this launch issue of Biotech Frontiers, we are recommending a basket of 10 biotech stocks to buy immediately.
Read More …